3.00
-0.03 (-0.99%)
| 前收盘价格 | 3.03 |
| 收盘价格 | 3.09 |
| 成交量 | 644,115 |
| 平均成交量 (3个月) | 687,361 |
| 市值 | 224,400,288 |
| 价格/销量 (P/S) | 1.56 |
| 股市价格/股市净资产 (P/B) | 0.560 |
| 52周波幅 | |
| 利润日期 | 4 Aug 2025 - 8 Aug 2025 |
| 营业毛利率 | -19.77% |
| 营业利益率 (TTM) | -61.02% |
| 稀释每股收益 (EPS TTM) | -0.420 |
| 季度收入增长率 (YOY) | -44.70% |
| 总债务/股东权益 (D/E MRQ) | 3.58% |
| 流动比率 (MRQ) | 12.34 |
| 营业现金流 (OCF TTM) | 27.37 M |
| 杠杆自由现金流 (LFCF TTM) | 12.04 M |
| 资产报酬率 (ROA TTM) | -4.80% |
| 股东权益报酬率 (ROE TTM) | -7.77% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 看跌 |
| Medical Instruments & Supplies (全球的) | 看跌 | 看跌 | |
| 股票 | OraSure Technologies, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -2.0 |
| 内部交易活动 | -3.0 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -1.20 |
|
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Small Value |
| 内部持股比例 | 4.83% |
| 机构持股比例 | 89.49% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| MCGRATH KENNETH J | - | 2.78 | -12,524 | -34,817 |
| 累积净数量 | -12,524 | |||
| 累积净值 ($) | -34,817 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 2.78 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MCGRATH KENNETH J | 职员 | 08 Aug 2025 | 处理 (-) | 12,524 | 2.78 | 34,817 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 05 Aug 2025 | 公告 | OraSure Announces Second Quarter 2025 Financial Results |
| 04 Aug 2025 | 公告 | OraSure Appoints Anne Messing as Chief Commercial Officer |
| 21 Jul 2025 | 公告 | OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th |
| 10 Jul 2025 | 公告 | OraSure Launches Novel Blood Collection Device for Proteomic Research |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合